Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Glaxo Sells U.S. Rights to Wellbutrin XL Drug to Biovail for $510 Million
Glaxo Sells U.S. Rights to Wellbutrin XL Drug to Biovail for $510 Million
Glaxo Sells U.S. Rights to Wellbutrin XL Drug to Biovail for $510 Million
Submitted by
admin
on May 6, 2009 - 6:14am
Source:
Bloomberg
News Tags:
GSK
Biovail
Wellbutrin
Headline:
Glaxo Sells U.S. Rights to Wellbutrin XL Drug to Biovail for $510 Million
Do Not Allow Advertisers to Use My Personal information
